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Illicit drug use with opiates in pregnancy is a major global health issue with neonatal withdrawal being a common complication.
Morphine is the main pharmacological agent administered for the treatment of neonatal withdrawal. In the past, morphine has
been considered by and large inert in terms of its long-term eﬀects on the central nervous system. However, recent animal and
clinicalstudies havedemonstratedthatopiatesexhibitsigniﬁcanteﬀectsonthegrowingbrain.Thisincludesdirect dose-dependent
eﬀects on reduction in brain size and weight, protein, DNA, RNA, and neurotransmitters—possibly as a direct consequence of
a number of opiate-mediated systems that inﬂuence neural cell diﬀerentiation, proliferation, and apoptosis. At this stage, we
are stuck between the devil and the deep blue sea. There are no real alternatives to pharmacological treatment with opiates and
other drugs for neonatal opiate withdrawal and opiate addiction in pregnant women. However, pending further rigorous studies
examining the potential harmful eﬀects of opiate exposure in utero and the perinatal period, prolonged use of these agents in the
neonatal period should be used judiciously, with caution, and avoided where possible.
1.Introduction
Illicit drug use in pregnancy and the associated adverse
eﬀectsforbothmotherand childare important publichealth
issues in most developed countries. Recent Australian data
has shown that the prevalence of newborns with neonatal
withdrawal has surged more than 30-fold over the past two
decades,causingamajorstrainonthehealthsystem[1].Opi-
ates and to a lesser extent barbiturates are the main pharma-
cological agents administered for the treatment of neonatal
withdrawal. In the past, these agents have been considered
by and large inert in terms of their long-term eﬀects on
the central nervous system [2–5]. However, a growing body
of evidence from animal studies and recent clinical studies
in children suggests a more cautious approach towards
uncritical use of these drugs for neonatal withdrawal.
2.CurrentApproachesto OpiateTreatmentof
Neonatal Withdrawal
Undoubtedly, neonatal withdrawal is a potentially fatal
condition, which requires early recognition and appropriate
pharmacological treatment [6]. It is accepted that neonatal
withdrawal requires treatment due to its associated mor-
bidity, increased incidence of seizures [7–11], diﬃculties
with weight gain [12–15], increase in infant mortality and
sudden infant death syndrome (SIDS) [11, 16–21], and
evidence of infant suﬀering [22]. With these potentially
serious consequences, an exclusively nonpharmacological
approach to neonatal abstinence cannot be recommended
and widespread use of pharmacological agents for neona-
tal withdrawal is the recognised and accepted practice
[6, 13, 23–29].
Monitoring of babies exposed to chronic intrauterine
amphetamines, cocaine, or opiates is generally recom-
m e n d e df o r5 – 7d a y sa f t e rb i r t h[ 30], with more than 50% of
newborns developingsymptoms that require treatment [31].
Treatment in the ﬁrst instance may include nonpharmaco-
logical measures such as swaddling or breastfeeding. Phar-
macological interventions using an opiate most commonly
or alternatively a barbiturate are then frequently added
[26, 29], with pharmacological management of neonatal
withdrawal required in 45–80% of cases [32]. A step-up2 International Journal of Pediatrics
approach usually follows with the aim to titrate medication
to an optimal level at which symptoms are controlled. Once
eﬀective levels are reached, a weaning process follows which
can last from a few days to several months.
3.DurationofOpiate Treatmentfor
Neonatal Withdrawal
Length of pharmacological treatment for weaning depends
on several factors, such as the maximum dose required
or individual withdrawal patterns. It also varies, quite
signiﬁcantly, with the type of weaning strategy employed.
For example, rapid weaning involves dose reduction several
times per week depending on tight and frequent assess-
ments for withdrawal symptoms. Rapid weaning is generally
performed in hospital and can be quite work intensive for
nursing staﬀ, parents and carers. On the other hand, slow
weaning has become a more frequent practice, with a weekly
or fortnightly dose reduction occurring in the home setting.
Slow weaning is often used with the rationale of minimising
the disruption to maternal-infant bonding by allowing a
more gradual reduction ofopiatesin the home environment,
as well as the advantage of reduced costs.
The downside of slow weaning, however, is the potential
formoreprolongedexposuretoeitheropiatesorbarbiturates
and increased cumulative doses in early infancy. From our
own review of 232 cases, the average length of treatment
was 49 days for those patients managed in the home setting
versus 23 days for in patient weaning. It is important to
note that this increased postnatal pharmacological exposure
is in addition to the already prolonged exposure to opiates
or other illicit drugs whilst in utero. At this stage, there is no
data to guide choice of one strategy over another (i.e., rapid
versus slow weaning). Therefore, choice of weaning strategy
remains subject to the resources and services available at
diﬀerent centres [25, 33].
As a result, the risks of prolonged and increased total
cumulative pharmacological exposure to opiates require
some attention, particularly given the growing body of




Opiates exhibit signiﬁcant eﬀects on the growing brain.
This includes direct dose-dependent eﬀects on reduc-
tion in brain size and weight, protein, DNA, RNA, and
neurotransmitters—possibly as a direct consequence of a
number ofopiate-mediated systems thatinﬂuence neuralcell
diﬀerentiation,proliferation, and apoptosis[32]. The animal
evidence also suggests that these adverse eﬀects on central
nervous system development translate into abnormalities in
later animal neurodevelopment and behaviour [34–39].
More speciﬁcally opiates appear to interfere with the
GABAergic system. While in the mature brain the primary
role of the GABAergic system is inhibition, in the immature
brain the GABAergic system is predominantly excitatory, a
function required for normal brain development. Chronic
opiate exposure in utero and in the perinatal period can
interfere with normal GABA system development and inﬂu-
ence brain excitability and seizure susceptibility [35, 40].
Excessive excitation of brain cells—excitotoxicity—is a well
established mechanism of cell injury and death, resulting
from animbalancebetweenexcitatoryandinhibitory signals.
Furthermore, the switch in GABA function is regulated by
certain transporter proteins, which have been implicated in
excessive excitation and opiate addiction [41].
Superimposed on an already excitatory and compro-
mised environment, prolonged treatment with medications
that enhance inhibition in a mature brain could para-
doxically lead to potentially damaging levels of excitation
in a developing newborn brain. Some evidence of poten-
tial adverse eﬀects due to enhanced GABAergic activation
includes recent association with impaired cognitive function
at 3 years and in utero exposure to valproic acid—an agent
that directly targets the GABA system [42].
5.ClinicalEvidenceforAdverseEffectsof
OpiatesinEarlyLife
Although animal data strongly suggests adverse neurode-
velopmental outcomes due to opiate exposure in early life,
clinical data in humans remains insuﬃcient, conﬂicting, and
inconclusive[28,43–48].Sofarthereislittleclinicalevidence
to support either harmful or benign long-term eﬀects of
opiate exposure in utero or the perinatal period. However,
t h eg r e a tc h a l l e n g eh e r ei st od i ﬀerentiate between harms
directly due to opiates [32, 46, 47, 49]a n di n d i r e c te ﬀects
associated with the medical and social complications that
cooccur with illicit drug use [2, 43–45, 50, 51].
Many studies do not control for social variables, such as
socioeconomic status, early childhood education, maternal
education level, and income, home social and psychological
environment or family stressors [49, 52–54]. Given the
enormous social challenges that face children raised in
a drug-exposed environment, it is not possible to draw
any meaningful conclusion about the relationship between
opiate exposure and harm without controlling for these
variables. Some studies attempted to eliminate the social
variables by matching children on social environment—
for example, by comparing drug-exposed children raised in
foster care to non-drug-exposed children [5, 49, 52–56].
However, this introduces additional confounders of foster
parents who may be more educated and provide greater
support to help overcome the initial adversity faced by the
drug-exposed child [55].
In addition to social variables, there are numerous other
potential maternal and neonatal confounders to match or
statistically control for in order to make valid comparisons
between exposed and nonexposed groups [44, 46, 47, 57–
59]. This includes, but is not limited to, confounders such
as, maternal age, nutrition status, IQ and psychiatric history,
neonatal birth weight, gestational age, perinatal compli-
cations and congenital and developmental anomalies, and
sources of bias, such as selection bias, for example, selecting
children who are already suspected of developmental delayInternational Journal of Pediatrics 3
[57]. Unfortunately, the majority of available studies are
limited or incomplete in their analysis and control for these
potential confounders [5, 33, 49, 53–56, 60–63].
In addition, most studies fail to diﬀerentiate between
exposure to heroin, methadone, or both heroin and
methadone, and no studies analyse for the diﬀerential eﬀect
of additional opiate exposure in the neonatal period. Much
of the research also fails to adequately discuss, analyse, or
control for the eﬀects of polydrug use [5, 33, 49, 53–56,
60–64]. Even the largest and most well-designed study—
the landmark Maternal Lifestyle Study—failed to adequately
account for the diﬀerential eﬀects of opiate as opposed to
cocaine exposure [65, 66]. Overall, it appears that control
for the main drug of interest (i.e., opiate versus other drug
exposure) is often lost in the complexity of attempting to
control for the myriad of maternal, neonatal, and social
variables found in this population.
In summary, the current clinical research on neurode-
velopmental outcomes of opiate exposure in utero and/or
the perinatal period is best limited to small studies and, at
worst, methodologically ﬂawed. This highlights the urgent
need for well-controlled, preferably large, studies in this
area that examine the relationship between opiate use,
maternal, neonatal, and social variables, and neurodevel-
opmental outcomes. The need is particularly urgent given
the increasing body of theoretical and animal research
suggesting likely harmful eﬀects of opiate exposure on later
neurodevelopment and behaviour.
6. Are ThereAlternativesto OpiateTreatment
forNeonatal Withdrawal?
The current guidelines certainly suggest that opiates are
the most eﬀective pharmacological agent in reducing the
symptoms of neonatal withdrawal [6, 13, 24, 26–28]. In
particular, it is acknowledged that opiates compared to other
pharmacological agents (e.g., phenobarbitone, diazepam,
chlorpromazine) appear to reduce the duration of treatment
[67–69], the need for a second agent to reduce withdrawal
symptoms [8, 68, 69], and the admission rate to neonatal
units[68, 69].They also may reducetheincidenceofseizures
[27]. It is generally agreed that opiates are superior to other
sedativeagentssuchaschlorpromazineanddiazepamincon-
trolling abstinence-associated seizures, preventing treatment
failure and the need for a second pharmacological agent
[24, 25, 27, 28]. They are also considered to have less adverse
eﬀects in the neonate compared to sedatives [6, 24]. If a
second agent is required, the current recommendations are
for the use of phenobarbitone [28] which, when combined
with opiates, may assist in the management of seizures,
improve behaviour and interaction [70], and reduce the
duration of therapy required to minimise symptoms [71].
It is also recommended that, as much as possible, the
pharmacological agent used to assist withdrawal should
match the agent of in utero addiction (e.g., opiates for opiate
addiction, phenobarbitone for amphetamine addiction, etc.)
[6, 13, 25].
Another pharmacological agent, which demonstrates
somepromise and mayhavethepotential tobean alternative
to opiates, is clonidine, an α2-adrenergic receptor agonist.
Preliminary trials havesuggestedthatclonidinecomparedto,
or inadditionto, opiatesmarkedly reducestreatment failure,
withdrawal symptoms, duration of therapy, and/or duration
of opiate use and maximum dosage required [72–74]. Given
the possible safety issues associated with clonidine, however,
the guidelines recommend that further clinical trials are




sea. Ontheonehand, methadonemaintenance treatment for
pregnant women who are illicit drug users has consistently
been shown to reduce harmful outcomes for both the
mother and newborn [3, 32, 58]. Furthermore, there are no
real alternatives to pharmacological treatment with opiates
and other drugs for neonatal opiate withdrawal and opiate
a d d i c t i o ni np r e g n a n tw o m e n .O nt h eo t h e rh a n d ,t h e r e
is increasing animal and theoretical evidence to challenge
the general assumption that opiates are a benign substance
to neurodevelopment and, at this stage, there is inadequate
clinical research to guide our prescription of opiates for this
already vulnerable and at-risk population.
As a result, pending further rigorous studies examining
the potential harmful eﬀects of opiate exposure in utero and
the perinatal period, prolonged use of these agents in the
neonatal period should be used judiciously, with caution,
and avoided where possible.
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